BRPI0909415A2 - derivados poli-substituídos de 2-aril -6-fenil-imidazo [1,2-a] piridinas poli-substituídos, o respectivo preparo e a prespectiva aplicação em terapêutica - Google Patents

derivados poli-substituídos de 2-aril -6-fenil-imidazo [1,2-a] piridinas poli-substituídos, o respectivo preparo e a prespectiva aplicação em terapêutica

Info

Publication number
BRPI0909415A2
BRPI0909415A2 BRPI0909415A BRPI0909415A BRPI0909415A2 BR PI0909415 A2 BRPI0909415 A2 BR PI0909415A2 BR PI0909415 A BRPI0909415 A BR PI0909415A BR PI0909415 A BRPI0909415 A BR PI0909415A BR PI0909415 A2 BRPI0909415 A2 BR PI0909415A2
Authority
BR
Brazil
Prior art keywords
substituted
poly
imidazo
phenyl
aryl
Prior art date
Application number
BRPI0909415A
Other languages
English (en)
Inventor
Malanda André
Almario Garcia Antonio
De Peretti Danielle
Rakotoarisoa Nathalie
Lardenois Patrick
Evanno Yannick
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39764952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909415(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0909415A2 publication Critical patent/BRPI0909415A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

derivados poli-substituídos de 2-aril -6- fenil-imidazo [1 ,2- a] piridinas poli-substituídos, o respectivo preparo e a respectiva aplicação em terapêutica compostos de fórmula (1): na qual: r1 representa: um grupo fenila ou um grupo naftila, esses dois grupos podendo eventualmente ser substituídos; x representa de 1 a 4 substituintes idênticos ou diferentes um do outro escolhido dentre hidrogênio, halogênio, (c1-c10) alquila, halo (c1-c10) alquila, (c1-c10) alcóxi, nrarb, ciano, nitro; r representa em posição 3, 5, 7, 8 do imidazo [1,2-a] piridina de 1 a 4 substituintes idênticos ou diferentes um do outro; rz e r3 representam, independentemente um do outro, um átomo de hidrogênio, um grupo (c1-c10) alquila eventualmente substituído; um grupo arila eventualmente substituído; r2 e x podem formar juntos com os átomos de carbono que os portam um ciclo carbonado de 5 a 7 átomos de carbono; r4 representa um átomo de hidrogênio, um grupo (c1-c10) alquila eventualmente substituído, ou um grupo arila, eventualmente substituído por um ou vários substituintes. utilização em terapêutica e processo de síntese.
BRPI0909415A 2008-03-21 2009-03-20 derivados poli-substituídos de 2-aril -6-fenil-imidazo [1,2-a] piridinas poli-substituídos, o respectivo preparo e a prespectiva aplicação em terapêutica BRPI0909415A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0801581A FR2928922B1 (fr) 2008-03-21 2008-03-21 Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
PCT/FR2009/000302 WO2009144394A1 (fr) 2008-03-21 2009-03-20 Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines polysubstitues, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
BRPI0909415A2 true BRPI0909415A2 (pt) 2019-01-15

Family

ID=39764952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909415A BRPI0909415A2 (pt) 2008-03-21 2009-03-20 derivados poli-substituídos de 2-aril -6-fenil-imidazo [1,2-a] piridinas poli-substituídos, o respectivo preparo e a prespectiva aplicação em terapêutica

Country Status (23)

Country Link
US (1) US8507520B2 (pt)
EP (1) EP2262769B1 (pt)
JP (1) JP5508385B2 (pt)
KR (1) KR20100129775A (pt)
CN (2) CN102036959B (pt)
AR (1) AR070993A1 (pt)
AU (1) AU2009253234B2 (pt)
BR (1) BRPI0909415A2 (pt)
CA (1) CA2719125C (pt)
CL (1) CL2009000696A1 (pt)
CO (1) CO6290657A2 (pt)
EA (1) EA201071112A1 (pt)
FR (1) FR2928922B1 (pt)
IL (1) IL208246A0 (pt)
MA (1) MA32247B1 (pt)
ME (1) ME01029B (pt)
MX (1) MX2010010316A (pt)
NZ (1) NZ588151A (pt)
SG (1) SG189679A1 (pt)
TW (1) TW200944202A (pt)
UY (1) UY31728A (pt)
WO (1) WO2009144394A1 (pt)
ZA (1) ZA201006728B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426441B2 (en) * 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2950345B1 (fr) * 2009-09-18 2011-09-23 Sanofi Aventis Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
US9295384B2 (en) * 2014-05-16 2016-03-29 Novartis Ag Imaging probes and associated devices, systems, and methods utilizing lever arm actuators
BR112018006005A2 (pt) * 2015-09-29 2018-10-30 Oncotherapy Science Inc composto bicíclico e uso do mesmo para inibição de suv39h2
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
SMT202500157T1 (it) 2018-03-30 2025-05-12 Incyte Corp Composti eterociclici come immunomodulatori
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
EP4370516A1 (en) * 2021-07-16 2024-05-22 Sanofi 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy
JP2024525791A (ja) * 2021-07-16 2024-07-12 サノフイ 治療に使用するためのイミダゾ［１，２－ｂ］［１，２，４］トリアゾール誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1651201A (en) * 1999-12-06 2001-06-18 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903106B1 (fr) * 2006-07-03 2010-07-30 Sanofi Aventis Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2928924B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques

Also Published As

Publication number Publication date
AU2009253234B2 (en) 2013-07-11
UY31728A (es) 2009-11-10
MX2010010316A (es) 2010-12-14
TW200944202A (en) 2009-11-01
MA32247B1 (fr) 2011-04-01
CO6290657A2 (es) 2011-06-20
KR20100129775A (ko) 2010-12-09
EP2262769A1 (fr) 2010-12-22
CN103193815A (zh) 2013-07-10
AU2009253234A1 (en) 2009-12-03
FR2928922A1 (fr) 2009-09-25
WO2009144394A8 (fr) 2010-10-14
IL208246A0 (en) 2010-12-30
CA2719125C (fr) 2016-07-26
JP5508385B2 (ja) 2014-05-28
EP2262769B1 (fr) 2014-11-05
US8507520B2 (en) 2013-08-13
CA2719125A1 (fr) 2009-12-03
ZA201006728B (en) 2011-11-30
NZ588151A (en) 2012-07-27
SG189679A1 (en) 2013-05-31
EA201071112A1 (ru) 2011-04-29
CL2009000696A1 (es) 2010-08-13
US20110065745A1 (en) 2011-03-17
AR070993A1 (es) 2010-05-19
WO2009144394A1 (fr) 2009-12-03
JP2011515382A (ja) 2011-05-19
CN102036959B (zh) 2013-05-22
ME01029B (me) 2012-10-20
CN102036959A (zh) 2011-04-27
FR2928922B1 (fr) 2010-04-23

Similar Documents

Publication Publication Date Title
BRPI0909415A2 (pt) derivados poli-substituídos de 2-aril -6-fenil-imidazo [1,2-a] piridinas poli-substituídos, o respectivo preparo e a prespectiva aplicação em terapêutica
MA32246B1 (fr) Dérivés polysubstitues de 2-aryl-6-phenyl-imidazo[1,2- a]pyridines, leur préparation et leur application en thérapeutique
MA32249B1 (fr) Dérivés polysubstitues de 2-heteroaryl-6-phenyl-imidazo[1,2- a]pyridines, leur préparation et leur application en thérapeutique
TW200942541A (en) Polysubstituted 6-heteroarylimidazo[1,2-α]pyridine derivatives, preparation thereof and therapeutic use thereof
TN2009000081A1 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2- α ] PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
EA201070072A1 (ru) ПРОИЗВОДНЫЕ 6-ЦИКЛОАМИНО-3-(ПИРИДИН-4-ИЛ)ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
EA201490580A1 (ru) Пирролбензодиазепины и их конъюгаты
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
CY1111868T1 (el) Παραγωγα ιμιδαζο[1,2-α] πυριδινο-2-καρβοξαμιδιων η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
DOP2011000061A (es) Compuestos de pirrol
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
MX2009011212A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
EA201170093A1 (ru) Замещенные n-оксидпиразиновые производные
ATE554147T1 (de) Neue organische fluoreszierende sulfonylharnstoff-benzoxazinon-pigmente
WO2007119001A3 (fr) Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique
BRPI0813809A2 (pt) derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica.
MX2013007462A (es) Procedimiento de preparacion de derivados de 3-alquilsulfinilbenzo ilo.
CO6400141A2 (es) Derivados de 2-piridin - 2 il pirazol- 3 (2h)-ona, su preparación y su aplicación en terapeútica com activadores de hif
TW200628450A (en) Pyridine derivatives, preparation thereof and therapeutic application thereof
DK1883640T3 (da) Fremgangsmåde til fremstilling af chlorider af phthalocyaninderivater der omfatter mindst en kvaternær ammoniumgruppe
BRPI0514235A (pt) derivados de pirrol, o respectivo preparo e a respectiva utilização em terapêutica
BRPI0518998A2 (pt) âmega-feniloctanamidas
EA201070818A1 (ru) ПРОИЗВОДНЫЕ N-ГЕТЕРОЦИКЛИЧЕСКИХ-6-ГЕТЕРОЦИКЛИЧЕСКИХ-ИМИДАЗО[1,2a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
DE60325480D1 (de) Verfahren zur herstellung von alkylidensubstituierten 1,4-dionderivaten
UA83638C2 (ru) Соединения 4-оксо-4,6,7,8-тетрагидропирроло[1,2-a]пиразин-6-карбоксамида, способ их получения и фармацевтическая композиция, которая их содержит

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2507 DE 22-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]